These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36083147)

  • 1. FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer.
    Gonzalez-Ericsson PI; Servetto A; Formisano L; Sánchez V; Mayer IA; Arteaga CL; Sanders ME
    Appl Immunohistochem Mol Morphol; 2022 Oct; 30(9):600-608. PubMed ID: 36083147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 4. Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.
    Göke F; Göke A; von Mässenhausen A; Franzen A; Sharma R; Kirsten R; Böhm D; Kristiansen G; Stenzinger A; Wynes M; Hirsch FR; Weichert W; Heasley L; Buettner R; Perner S
    Digestion; 2013; 88(3):172-81. PubMed ID: 24135816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
    Mouron S; Manso L; Caleiras E; Rodriguez-Peralto JL; Rueda OM; Caldas C; Colomer R; Quintela-Fandino M; Bueno MJ
    Breast Cancer Res; 2021 Feb; 23(1):21. PubMed ID: 33579347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Drago JZ; Formisano L; Juric D; Niemierko A; Servetto A; Wander SA; Spring LM; Vidula N; Younger J; Peppercorn J; Yuen M; Malvarosa G; Sgroi D; Isakoff SJ; Moy B; Ellisen LW; Iafrate AJ; Arteaga CL; Bardia A
    Clin Cancer Res; 2019 Nov; 25(21):6443-6451. PubMed ID: 31371343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma.
    Jang M; Kim E; Choi Y; Lee H; Kim Y; Kim J; Kang E; Kim SW; Kim I; Park S
    Breast Cancer Res; 2012 Aug; 14(4):R115. PubMed ID: 22863309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.
    Lehnen NC; von Mässenhausen A; Kalthoff H; Zhou H; Glowka T; Schütte U; Höller T; Riesner K; Boehm D; Merkelbach-Bruse S; Kirfel J; Perner S; Gütgemann I
    Histopathology; 2013 Aug; 63(2):157-66. PubMed ID: 23808822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma.
    Brunello E; Brunelli M; Bogina G; Caliò A; Manfrin E; Nottegar A; Vergine M; Molino A; Bria E; Massari F; Tortora G; Cingarlini S; Pedron S; Chilosi M; Zamboni G; Miller K; Martignoni G; Bonetti F
    J Exp Clin Cancer Res; 2012 Dec; 31(1):103. PubMed ID: 23270564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer.
    Elakad O; Lois AM; Schmitz K; Yao S; Hugo S; Lukat L; Hinterthaner M; Danner BC; von Hammerstein-Equord A; Reuter-Jessen K; Schildhaus HU; Ströbel P; Bohnenberger H
    Cancer Med; 2020 May; 9(10):3574-3583. PubMed ID: 32207251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
    Formisano L; Lu Y; Servetto A; Hanker AB; Jansen VM; Bauer JA; Sudhan DR; Guerrero-Zotano AL; Croessmann S; Guo Y; Ericsson PG; Lee KM; Nixon MJ; Schwarz LJ; Sanders ME; Dugger TC; Cruz MR; Behdad A; Cristofanilli M; Bardia A; O'Shaughnessy J; Nagy RJ; Lanman RB; Solovieff N; He W; Miller M; Su F; Shyr Y; Mayer IA; Balko JM; Arteaga CL
    Nat Commun; 2019 Mar; 10(1):1373. PubMed ID: 30914635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.
    Göke F; Franzen A; Hinz TK; Marek LA; Yoon P; Sharma R; Bode M; von Maessenhausen A; Lankat-Buttgereit B; Göke A; Golletz C; Kirsten R; Boehm D; Vogel W; Kleczko EK; Eagles JR; Hirsch FR; Van Bremen T; Bootz F; Schroeck A; Kim J; Tan AC; Jimeno A; Heasley LE; Perner S
    Clin Cancer Res; 2015 Oct; 21(19):4356-64. PubMed ID: 26015511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.
    Tomiguchi M; Yamamoto Y; Yamamoto-Ibusuki M; Goto-Yamaguchi L; Fujiki Y; Fujiwara S; Sueta A; Hayashi M; Takeshita T; Inao T; Iwase H
    Cancer Sci; 2016 Apr; 107(4):491-8. PubMed ID: 26801869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lucitanib for the Treatment of HR
    Hui R; Pearson A; Cortes J; Campbell C; Poirot C; Azim HA; Fumagalli D; Lambertini M; Daly F; Arahmani A; Perez-Garcia J; Aftimos P; Bedard PL; Xuereb L; Scheepers ED; Vicente M; Goulioti T; Loibl S; Loi S; Pierrat MJ; Turner NC; Andre F; Curigliano G
    Clin Cancer Res; 2020 Jan; 26(2):354-363. PubMed ID: 31619444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
    Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer.
    Thomas A; Lee JH; Abdullaev Z; Park KS; Pineda M; Saidkhodjaeva L; Miettinen M; Wang Y; Pack SD; Giaccone G
    J Thorac Oncol; 2014 Apr; 9(4):567-71. PubMed ID: 24736083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
    Turner N; Pearson A; Sharpe R; Lambros M; Geyer F; Lopez-Garcia MA; Natrajan R; Marchio C; Iorns E; Mackay A; Gillett C; Grigoriadis A; Tutt A; Reis-Filho JS; Ashworth A
    Cancer Res; 2010 Mar; 70(5):2085-94. PubMed ID: 20179196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
    Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
    Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
    Wynes MW; Hinz TK; Gao D; Martini M; Marek LA; Ware KE; Edwards MG; Böhm D; Perner S; Helfrich BA; Dziadziuszko R; Jassem J; Wojtylak S; Sejda A; Gozgit JM; Bunn PA; Camidge DR; Tan AC; Hirsch FR; Heasley LE
    Clin Cancer Res; 2014 Jun; 20(12):3299-309. PubMed ID: 24771645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.